간문맥 종양혈전을 동반한 간세포암종의 예후 인자
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 서상준 | - |
dc.contributor.author | 임형준 | - |
dc.contributor.author | 이동원 | - |
dc.contributor.author | 현종진 | - |
dc.contributor.author | 정영걸 | - |
dc.contributor.author | 김지훈 | - |
dc.contributor.author | 서연석 | - |
dc.contributor.author | 연종은 | - |
dc.contributor.author | 변관수 | - |
dc.contributor.author | 엄순호 | - |
dc.date.accessioned | 2021-09-03T13:00:32Z | - |
dc.date.available | 2021-09-03T13:00:32Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/85739 | - |
dc.description.abstract | Background/Aims: Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) exhibits poor prognosis. The aim of this study is to evaluate factors associated with survival of HCC patients with PVTT to suggest better therapeutic options. Methods: Patients with HCC which were newly diagnosed at three tertiary hospitals between January 2004 and December 2012, were reviewed retrospectively. Among them, Barcelona Clinic of Liver Cancer stage C patients with PVTT were identified. Factors affecting overall survival (OS) were analyzed and efficacies of the treatment modalities were compared. Results: Four hundred sixty five patients with HCC and PVTT were included. Liver function, tumor burden, presence of extrahepatic tumor, alfa fetoprotein, and treatment modalities were significant factors associated with OS. Treatment outcomes were different according to the initial modalities. OS of the patients who received hepatic resection, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), sorafenib, systemic cytotoxic chemotherapy, radiation therapy (without combination), and supportive care were 27.8, 7.1, 6.7, 5.3, 2.5, 3.0, 1.8, and 0.9 months, respectively (P<0.001). Curative-intent treatments such as hepatic resection or RFA were superior to noncurativeintent treatments (P<0.001). TACE or HAIC was superior to sorafenib or systemic chemotherapy (P<0.001). Combining radiotherapy to TACE or HAIC did not provide additional benefit on OS (P=0.096). Conclusions: Treatment modalities as well as baseline factors significantly influenced on OS of HCC patients with PVTT. Whenever possible, curative intent treatments should be preferentially considered. If unable, locoregional therapy would be a better choice than systemic therapy in HCC patients with PVTT. (J Liver Cancer 2017;17:60-71) | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | 대한간암학회 | - |
dc.title | 간문맥 종양혈전을 동반한 간세포암종의 예후 인자 | - |
dc.title.alternative | Factors Affecting Prognosis of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Implications for Future Therapeutic Strategies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 현종진 | - |
dc.contributor.affiliatedAuthor | 엄순호 | - |
dc.identifier.bibliographicCitation | Journal of Liver Cancer, v.17, no.1, pp.60 - 71 | - |
dc.relation.isPartOf | Journal of Liver Cancer | - |
dc.citation.title | Journal of Liver Cancer | - |
dc.citation.volume | 17 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 60 | - |
dc.citation.endPage | 71 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002208061 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Portal vein | - |
dc.subject.keywordAuthor | Thrombosis | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.